Clinical Pharmacokinetics and Pharmacodynamics of Warfarin
- 488 Downloads
A pharmacokinetic model for the absorption, distribution, and elimination of warfarin. Warfarin is essentially completely absorbed, reaching a maximum plasma concentration between 2 and 6 hours. It distributes into a small volume of distribution (10 L/70kg) and is eliminated by hepatic metabolism with a very small clearance (0.2 L/h/70kg). The elimination half-life is about 35 hours.
A pharmacodynamic model for the effect of warfarin on the synthesis of clotting factors (prothrombin complex). Prothrombin complex synthesis is inhibited 50% at a warfarin concentration of about 1.5 mg/L. Warfarin concentrations associated with therapeutic anticoagulation are of similar magnitude.
A physiological model for the synthesis and degradation of the prothrombin complex. The synthesis rate is about 5%/h/70kg and the elimination half-life estimated from changes in prothrombin time is approximately 17 hours. On average it will take 3 days for the anticoagulant effect of warfarin to reach a stable value when warfarin concentrations are constant.
A model for the relationship between the activity of prothrombin complex and the prothrombin time. In general there is a hyperbolic relationship between these quantities. Its exact shape depends upon the method used for measuring the prothrombin time.
Attempts to integrate these models into a single system have used essentially the same pharmacokinetic, physiological, and prothrombin activity models. Four distinct pharmacodynamic models have been proposed: linear, log-linear, power and Emax. One might be preferred on theoretical grounds (Emax) but its performance is not clearly different from the others.
Empirical methods for warfarin dose prediction as well as those based on the combined pharmacokinetic-pharmacodynamic-physiological-prothrombin system have been proposed. Only one (which was also the first) [Sheiner 1969] has been adequately described and compared with the performance of an unaided physician. The programme compared favourably with decisions made by those physicians normally responsible for adjusting warfarin dose, but was not tested prospectively.
A sizeable body of theoretical and experimental observations has contributed to our understanding of the warfarin dose-effect relationship. It remains to be demonstrated that any alternative method is superior to the traditional empirical approach to warfarin dose adjustment.
KeywordsWarfarin Clinical Pharmacology Prothrombin Prothrombin Time Pharmacodynamic Model
Unable to display preview. Download preview PDF.
- Aarons L, Chan E, Rowland M, Breckenridge A, Serlin M. Relationship between vitamin K-dependent clotting factors and warfarin anticoagulation at steady state. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 755, p. 55, 1986Google Scholar
- Abbrecht PH, Huhta JC. Clinical application of a mathematical model for warfarin dosage determination. Bioengineering Program Report, University of Michigan, Ann Arbor, 1972Google Scholar
- Barr W. Presented at the ASHP Institute on Advanced Pharmacokinetics, Lexington, 1975Google Scholar
- Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. Journal of Pharmacology and Experimental Therapeutics 210: 323–326, 1979bGoogle Scholar
- Carter BL, Taylor JW, Reinders TP. Evaluation of two methods to predict maintenance warfarin. Drug Intelligence and Clinical Pharmacy 18: 510, 1984Google Scholar
- Chan E, O’Reilly R, Rowland M. Stereochemical aspects of warfarin in man: a combined pharmacokinetic-pharmacodynamic model. British Journal of Clinical Pharmacology 19: 545P, 1984aGoogle Scholar
- Chan E, Pegg M, Mackay AD, Cole RB, Rowland M. Stereochemical aspects of warfarin in patients receiving chronic therapy. British Journal of Clinical Pharmacology 19: 571P, 1984bGoogle Scholar
- Choonara IA, Haynes BP, Cholertons, Breckenridge AM, Park BK, et al. Dissociation between vitamin K1 2,3-epoxide reductase and clotting factor synthesis with warfarin. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 756, p. 55, 1986Google Scholar
- Coleman R, Murray W, Hong R, Mitsouka C, Daschbach M, et al. Predicting response to warfarin. Thrombosis and Haemostasis 54: 79, 1985Google Scholar
- Deykin D. ‘No-Load’ warfarin therapy. New England Journal of Medicine 283: 1346, 1970bGoogle Scholar
- Dickson RB, King RW, Suthers MB. Warfarin: predicting maintenance doses. Australian Journal of Hospital Pharmacy 14: 30–31, 1984Google Scholar
- Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Lancet 288: 1268–1270, 1984Google Scholar
- Fischer AM, Dautzenberg N, Pertuiset D, Ganeval D, Houin G. Pharmacolinetics of warfarin in the nephrotic syndrome and effect on vitamin-K dependent clotting factors. Thrombosis and Haemostatis 54: 82, 1985Google Scholar
- Gallus A, Jackaman J, Goodall K, Tillen J. The optimal duration of heparin treatment for venous thromboembolism. Thrombosis and Haemostasis 50: 52, 1983Google Scholar
- Holford NHG. Rational warfarin dosing: a pharmacokinetic-pharmacodynamic analysis. Abstract. Clinical Pharmacology and Therapeutics 39: 199, 1986Google Scholar
- International Committee for Standardisation in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thrombosis and Haemostasis 51: 155–156, 1985Google Scholar
- Mungall D, Marshall J, Ludden TM, Hawkins DW, Crawford MH. Population kinetics of warfarin. 2nd World Conference on Clinical Pharmacology and Therapeutics, Washington DC, July 1983. Abstract No. 256, p. 44, 1983Google Scholar
- Mungall DR. Predicting prothrombin time response to warfarin, Biotrack Information Bulletin, Biotrack, Inc., Sunnyvale, November 1984Google Scholar
- Murray B, McWaters D, Coleman R, Ludden T, Mungall D. Pharmacodynamics of warfarin. Clinical Pharmacology and Therapeutics 37: 215, 1985Google Scholar
- Nagashima R, O’Reilly RA, Levy G. Kinetics of pharmacological effects in man: the anticoagulant action of warfarin. Clinical Pharmacology 10: 22–35, 1969Google Scholar
- O’Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In Gilman AG et al. (Eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
- Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In Evans et al. (Eds) Applied Pharmacokinetics, 2nd ed., Applied Therapeutics Inc., San Francisco, 1986Google Scholar
- Porter RS, Lowenthal DT, Saris SD, Conry KC, Bies C, et al. Pharmacokinetic and pharmacodynamic analysis of warfarin in human subjects. Clinical Pharmacology and Therapeutics 37: 221, 1985Google Scholar
- Quick AJ. Discussion. In Flynn (Ed.) Blood clotting and allied problems. Transactions of the First Conference, pp. 85–88, Josiah Macy Jr. Foundation, New York, 1948Google Scholar
- Sawyer WT. Warfarin. In Mungall (Ed.) Applied Clinical Pharmacokinetics, pp. 187–222, Raven Press, 1983Google Scholar
- Shepherd AMM, Wilson N, Stevenson IH. Warfarin sensitivity in the elderly. In Crooks & Stevenson (Eds) Drugs and the elderly, University Park Press, Baltimore, 1979Google Scholar
- Smith LH. Hemorrhagic diseases. In Page & Culver (Eds) Syllabus of laboratory examinations in clinical diagnosis, p. 199, Harvard University Press, Harvard, 1961Google Scholar
- Spaethe R, Strauss J. The determination of the international sensitivity index (ISI) for conversion of prothrombin time (PT) into international normalized ratio (INR). Comparative studies with high and low factor sensitive thromboplastins. Thrombosis and Haemostasis 54: 80, 1985Google Scholar
- van den Besselaar AMHP, Broekmans AW, Hoekstra-Schuman M, Jansen-Gruter R, Loeliger EA. Thromboplastin-dependent variation of the normalized prothrombin time (INR) in orally anticoagulated patients. Abstract. Thrombosis and Haemostasis 54: 80, 1985Google Scholar